Bowman & Co S.C. Trims Stake in Edwards Lifesciences Corporation $EW

Key Points

• Bowman & Co S.C. has cut its stake in Edwards Lifesciences Corporation by 37.8%, selling off over 5,000 shares, and now holds shares worth approximately $660,000.
• Edwards Lifesciences reported a quarterly earnings per share (EPS) of $0.67, exceeding analyst expectations, with a revenue of $1.53 billion, up 11.9% year-over-year.
• Research analysts have raised their price targets for Edwards Lifesciences, with estimates now ranging from $80.00 to $95.00, reflecting a consensus rating of "Moderate Buy".

Bowman & Co S.C. lowered its position in Edwards Lifesciences Corporation (NYSE:EW - Free Report) by 37.8% in the 2nd quarter, according to its most recent 13F filing with the SEC. The firm owned 8,440 shares of the medical research company's stock after selling 5,138 shares during the period. Bowman & Co S.C.'s holdings in Edwards Lifesciences were worth $660,000 at the end of the most recent quarter.

Several other hedge funds also recently bought and sold shares of EW. Quantbot Technologies LP bought a new position in Edwards Lifesciences in the 1st quarter worth $26,000. Vega Investment Solutions bought a new position in Edwards Lifesciences in the 4th quarter worth $27,000. SouthState Corp bought a new position in Edwards Lifesciences in the 1st quarter worth $27,000. Global X Japan Co. Ltd. boosted its holdings in Edwards Lifesciences by 116.1% in the 1st quarter. Global X Japan Co. Ltd. now owns 402 shares of the medical research company's stock worth $29,000 after buying an additional 216 shares during the period. Finally, Tradewinds Capital Management LLC boosted its holdings in Edwards Lifesciences by 102.5% in the 1st quarter. Tradewinds Capital Management LLC now owns 405 shares of the medical research company's stock worth $29,000 after buying an additional 205 shares during the period. Institutional investors own 79.46% of the company's stock.

Edwards Lifesciences Stock Down 1.9%

Shares of NYSE EW opened at $76.10 on Tuesday. The firm's 50-day moving average price is $78.91 and its 200-day moving average price is $75.48. The company has a current ratio of 4.68, a quick ratio of 3.87 and a debt-to-equity ratio of 0.06. The stock has a market capitalization of $44.68 billion, a price-to-earnings ratio of 10.95, a P/E/G ratio of 3.74 and a beta of 1.07. Edwards Lifesciences Corporation has a 12-month low of $64.00 and a 12-month high of $83.00.

Edwards Lifesciences (NYSE:EW - Get Free Report) last announced its earnings results on Thursday, July 24th. The medical research company reported $0.67 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.62 by $0.05. The firm had revenue of $1.53 billion for the quarter, compared to analysts' expectations of $1.49 billion. Edwards Lifesciences had a net margin of 72.96% and a return on equity of 15.01%. The business's revenue was up 11.9% compared to the same quarter last year. During the same period in the prior year, the company earned $0.70 EPS. Edwards Lifesciences has set its Q3 2025 guidance at 0.540-0.60 EPS. FY 2025 guidance at 2.400-2.500 EPS. On average, equities research analysts anticipate that Edwards Lifesciences Corporation will post 2.45 EPS for the current fiscal year.

Insider Transactions at Edwards Lifesciences

In related news, VP Daniel J. Lippis sold 4,114 shares of the stock in a transaction dated Monday, July 28th. The shares were sold at an average price of $79.46, for a total value of $326,898.44. Following the sale, the vice president directly owned 22,002 shares of the company's stock, valued at $1,748,278.92. This represents a 15.75% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, insider Larry L. Wood sold 8,950 shares of the stock in a transaction dated Monday, August 18th. The stock was sold at an average price of $78.06, for a total transaction of $698,637.00. Following the completion of the sale, the insider directly owned 206,900 shares in the company, valued at $16,150,614. This trade represents a 4.15% decrease in their ownership of the stock. The disclosure for this sale can be found here. Corporate insiders own 0.34% of the company's stock.

Wall Street Analysts Forecast Growth

Several research analysts recently weighed in on EW shares. Piper Sandler upped their target price on shares of Edwards Lifesciences from $83.00 to $90.00 and gave the stock an "overweight" rating in a report on Friday, July 25th. Wells Fargo & Company increased their price objective on shares of Edwards Lifesciences from $84.00 to $88.00 and gave the company an "overweight" rating in a report on Thursday, August 7th. William Blair raised shares of Edwards Lifesciences to a "strong-buy" rating in a report on Friday, July 25th. Barclays increased their price objective on shares of Edwards Lifesciences from $90.00 to $95.00 and gave the company an "overweight" rating in a report on Friday, July 25th. Finally, Evercore ISI increased their price objective on shares of Edwards Lifesciences from $77.00 to $80.00 and gave the company an "in-line" rating in a report on Friday, July 25th. Three investment analysts have rated the stock with a Strong Buy rating, eleven have given a Buy rating, nine have given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, Edwards Lifesciences presently has a consensus rating of "Moderate Buy" and an average price target of $86.26.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.

Want to see what other hedge funds are holding EW? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Edwards Lifesciences Corporation (NYSE:EW - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.